<DOC>
	<DOCNO>NCT02660866</DOCNO>
	<brief_summary>This Phase 4 , randomize clinical trial evaluate whether addition Vorapaxar 2.08 mg daily vs. placebo daily background antiplatelet therapy , prescribe 6 month patient establish peripheral artery disease ( PAD ) Intermittent Claudication ( IC ) treat standard medical therapy ( SMT ) would lead improvement peak walk time ( PWT ) .</brief_summary>
	<brief_title>Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation ( XLPAD-TRACE Trial )</brief_title>
	<detailed_description>Primary trial objective : To evaluate whether addition Vorapaxar 2.08 mg daily vs. placebo daily background antiplatelet therapy , prescribe 6 month patient establish PAD IC treat standard medical therapy ( SMT ) would lead improvement peak walk time ( PWT ) Study endpoint Primary endpoint : Change baseline 6 month PWT grade treadmill test ( GTT per Gardner protocol ) participant enrolled test control arm study Secondary endpoint - Change baseline 6 month claudication onset time ( COT ) GTT participant enrol test control arm study . - Change baseline 6 month walk impairment questionnaire distance score ( WIQ ) participant enrolled test control arm study . - Change baseline 6 month self-reported quality life score use Medical Outcomes Study 12-Item Short form survey ( SF-12 ) participant enrolled test control arm study Tertiary endpoint - The first occurrence clinically indicate low extremity endovascular surgical revascularization procedure entire study duration post-randomization participant enrol test control arm study . - The first occurrence all-cause death , MI , ischemic stroke entire study duration post-randomization participant enrol test control arm study . - The first occurrence severe bleeding define accord Global Utilization Streptokinase Tissue plasminogen activator Occluded coronary artery ( GUSTO ) classification entire study duration post-randomization participant enrol test control arm study .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Vorapaxar</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Prescreening criterion Laboratory value available ≤ 1 year date screening : hemoglobin ≥9g , platelet count &gt; 50,000 mm3 &lt; 600,000 mm3 No history stroke transient ischemic attack ( TIA ) No allergy aspirin ≥40 year age Presence document PAD ABI &lt; 0.80 rest ≥20 % drop claudication limit exercise ABI limb one follow criterion correspond limb : i.Prior surgical and/or endovascular low extremity intervention ( infrarenal aorta pedal artery ) ii . Known presence flowlimiting stenosis ( ≥70 % ) clinically indicate angiography , compute tomographic ( CT ) magnetic resonance imaging ( MRI ) test Duplex ultrasonography ( DUS ) define standard clinical criterion low extremity artery Documented IC Rutherford/Becker ( RC ) category ≥2 Presence two list class agent [ angiotensin convert enzyme inhibitor ( ACEI ) , angiotensin receptor blocker ( ARB ) , statin therapy betablocker drug ] No MI percutaneous coronary intervention ( PCI ) DES within past 11 month No planned surgical endovascular procedure treatment IC expect duration study No warfarin chronic oral anticoagulant use within last 14 day No use ticagrelor , clopidogrel , prasugrel ticlopidine within last 7 day No contraindication ( ) use antithrombin antiplatelet agent ( history intracerebral hemorrhage ICH , presence intracerebral mass , recent &lt; 12 week gastrointestinal bleed require blood transfusion , blood transfusion within last 6 week , trauma require surgery within last 4 week surgical endovascular procedure within last 4 week No use cilostazol and/or pentoxyphilline within last 7 day Severe psychiatric behavioral illness judgement investigator precludes study participation No history major minor amputation Severe heart , vascular lung disease discretion investigator precludes study participation . Ability walk least 15 min/day , least 3 days/week , ≥20 steps/min Inclusion criterion Treadmill PWT= 210 min Gardner protocol Estimated survival ≥1 year judgment site investigator Use least one aspirin dose within least 5 day prior randomization 325 mg dose aspirin naïve patient ( 05 day prior aspirin use ) least one aspirin dose prior randomization 81 mg dose patient chronic ( &gt; 5 day ) aspirin therapy ( clinically indicate dos ) . Presence two list class agent [ angiotensin convert enzyme inhibitor ( ACEI ) , angiotensin receptor blocker ( ARB ) , statin therapy betablocker drug ] . As part SMT , dose discretion clinical provider ( ) MI percutaneous coronary intervention ( PCI ) DES within past 11 month Positive pregnancy test Planned surgical endovascular procedure treatment IC Warfarin chronic oral anticoagulant use within 14 day Use Ticagrelor , Clopidogrel , Prasugrel Ticlopidine within 7 day Contraindication ( ) use antithrombin antiplatelet agent ( history intracerebral hemorrhage ICH , presence intracerebral mass , recent &lt; 12 week gastrointestinal bleed require blood transfusion , blood transfusion within last 6 week , trauma require surgery within last 4 week surgical endovascular procedure within last 4 week Use cilostazol and/or pentoxyphilline within 7 day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>intermittent claudication</keyword>
	<keyword>randomize control trial</keyword>
</DOC>